Dextrose Monohydrate 5% Injection Shortage: Current Availability and Manufacturer Updates
According to the U.S. Census Bureau's American Community Survey (ACS) 5-year estimates, the CDC PLACES population-level health analysis, and the CMS Hospital Compare quality data, Areazine publishes editorial articles drawing on more than 19,000 U.S. city profiles. See our methodology for full source attribution and refresh cadence.
The FDA has reported an ongoing shortage of Dextrose Monohydrate 5% Injection, with mixed availability across several major pharmaceutical manufacturers.
What this FDA drug-shortage notice tells you, and what most readers miss
This notice was issued by FDA on February 11, 2026 and geographically references United States. Its severity classification of "medium" signals how the issuing agency weighs the risk of harm if no action is taken — "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to — Drug Shortages — determines the regulatory framework behind it, which shapes what remedies (refunds, replacements, recalls, evacuations) are available to affected individuals and who holds statutory responsibility for enforcement.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to read it as a data point about the issuing system: how quickly FDA detected the hazard, how precise the geographic or product-identifier scope is, and whether similar notices have clustered in the same category or region in the last 90 days. Cluster patterns frequently precede a broader regulatory action — a single localized FDA drug-shortage notice is isolated; three of them within a quarter often indicate a supply-chain, infrastructure, or seasonal driver that will keep producing notices until something structural changes.
For decision-making, Areazine pairs each alert with the original agency URL, the full agency name, and a timestamp so you can verify the notice against the primary source before acting on it. Tags on this item (drug-shortage, fda, medication, Dextrose-Monohydrate) map to related alerts in the same area of risk — browsing them together gives a clearer picture than any single notice alone, because the shape of an ongoing issue only becomes visible across multiple sequential alerts.
What's in Shortage
As of the latest update, Dextrose Monohydrate 5% Injection (Brand Name: DEXTROSE) is currently listed in shortage. This medication is an injection used across several therapeutic categories, including Endocrinology, Metabolism, Gastroenterology, and Pediatrics. While many presentations remain available, specific product codes from certain manufacturers are currently unavailable or have been discontinued.
Which Manufacturers Are Affected
Several manufacturers supply this medication, with varying levels of availability:
- Baxter Healthcare: Reports mixed availability. While many presentations are available, NDC 0338-0066-20 and NDC 0338-0062-30 are currently unavailable with an estimated availability date to be determined. NDC 0338-9143-30 has been discontinued. (Contact: 888-229-0001)
- Otsuka ICU Medical LLC: All listed presentations are currently available. These products are distributed by ICU Medical. (Contact: 1-866-829-9025 or ProductAvailability@icumed.com)
- B. Braun Medical Inc.: All listed presentations are currently available. (Contact: 800-227-2862)
- Fresenius Kabi USA, LLC: Most presentations are available. However, NDC 65219-464-50 is listed as unavailable, though product with a 3-month expiry (3/31/2026) may be available by request. (Contact: 888-386-1300)
Why There's a Shortage
Specific reasons for the overall shortage were not provided by the FDA. However, Baxter Healthcare noted the discontinuation of the manufacture of one specific presentation (NDC 0338-9143-30). For other unavailable presentations, the estimated recovery dates are currently listed as "To Be Determined."
What Patients Should Do
If you or a family member are prescribed Dextrose Monohydrate 5% Injection, please consider the following steps:
- Consult your healthcare provider: Always speak with your doctor or clinical team regarding your treatment plan and any concerns about medication supply.
- Talk to your pharmacist: Pharmacists have the most up-to-date information on local inventory and can check with various wholesalers.
- Contact manufacturers: If a specific presentation is required, you may use the contact information provided above to inquire about current stock levels.
Disclaimer: Patients should consult their healthcare provider for medical advice and before making any changes to their treatment.
Source
Information provided by the FDA Drug Shortage Database.
Initial Posting Date: 02/14/2022
Last Updated: 02/02/2026
Original source: FDA Official Notice ↗
Related Drug Shortages
All Drug Shortages →Frequently Asked Questions
Common questions about this FDA drug-shortage notice.
What is this FDA drug-shortage notice about? ▾
Which agency issued this alert? ▾
How severe is this alert? ▾
What area is affected? ▾
Where can I find more Drug Shortages updates? ▾
Primary source data
EPA Outdoor Air Quality Data
Federal monitoring network — every measurement we report
AirNow (EPA / NOAA)
Real-time AQI for every monitored U.S. location
National Weather Service
Active watches, warnings, and advisories — NOAA
CDC Air Quality & Health
Health-impact reference behind every AQI category